State Street
FHTX icon

State Street’s Foghorn Therapeutics FHTX Stock Holding History

State Street’s Portfolio FHTX Stock Details FHTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$3.4M Buy
697,469
+17,682
+3% +$78.5K ﹤0.01% 3167
2026
Q1 		$3.25M Buy
679,787
+61,121
+10% +$336K ﹤0.01% 3130
2025
Q4 		$3.34M Sell
618,666
-18,482
-3% -$83.8K ﹤0.01% 3155
2025
Q3 		$3.12M Buy
637,148
+93,501
+17% +$496K ﹤0.01% 3185
2025
Q2 		$2.56M Sell
543,647
-42,570
-7% -$178K ﹤0.01% 3223
2025
Q1 		$2.14M Buy
586,217
+18,850
+3% +$85.9K ﹤0.01% 3220
2024
Q4 		$2.68M Buy
567,367
+61,422
+12% +$447K ﹤0.01% 3221
2024
Q3 		$4.71M Buy
505,945
+23,630
+5% +$171K ﹤0.01% 2999
2024
Q2 		$2.77M Buy
482,315
+44,651
+10% +$266K ﹤0.01% 3187
2024
Q1 		$2.94M Buy
437,664
+15,034
+4% +$83.5K ﹤0.01% 3143
2023
Q4 		$2.73M Sell
422,630
-11,240
-3% -$48.5K ﹤0.01% 3209
2023
Q3 		$2.17M Sell
433,870
-5,397
-1% -$41.6K ﹤0.01% 3293
2023
Q2 		$3.09M Buy
439,267
+29,754
+7% +$208K ﹤0.01% 3218
2023
Q1 		$2.54M Buy
409,513
+5,375
+1% +$35.2K ﹤0.01% 3259
2022
Q4 		$2.58M Buy
404,138
+32,520
+9% +$245K ﹤0.01% 3297
2022
Q3 		$3.19M Buy
371,618
+1,586
+0.4% +$20.4K ﹤0.01% 3270
2022
Q2 		$5.03M Buy
370,032
+51,807
+16% +$669K ﹤0.01% 3101
2022
Q1 		$4.85M Buy
318,225
+15,651
+5% +$215K ﹤0.01% 3195
2021
Q4 		$6.92M Buy
302,574
+77,554
+34% +$1.11M ﹤0.01% 3094
2021
Q3 		$3.13M Buy
225,020
+35,621
+19% +$394K ﹤0.01% 3480
2021
Q2 		$2.02M Buy
189,399
+80,300
+74% +$875K ﹤0.01% 3546
2021
Q1 		$1.44M Buy
109,099
+7,303
+7% +$120K ﹤0.01% 3545
2020
Q4 		$2.06M Buy
+101,796
New +$1.95M ﹤0.01% 3367

Other funds holding FHTX

FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
EC
Euclidean Capital New York $440M AUM 28.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return

State Street's FHTX Position: Q2 2026 in Review

State Street increased its Foghorn Therapeutics (FHTX) stake by 2.6% in Q2 2026, buying an estimated $78.5K and bringing the position to 697,469 shares worth $3.4M. The position accounts for ﹤0.01% of the portfolio, ranked #3167.

State Street first reported a position in FHTX in Q4 2020 and has held it in 23 quarters since. The position peaked at $6.92M in Q4 2021. 103 funds tracked by Wall St. Rank hold FHTX as of Q2 2026.

  • State Street held 697,469 shares of Foghorn Therapeutics worth $3.4M as of Q2 2026.
  • State Street bought 17,682 Foghorn Therapeutics shares in Q2 2026, an estimated $78.5K.
  • Foghorn Therapeutics made up ﹤0.01% of State Street's portfolio in Q2 2026, its #3167 holding.
  • State Street first reported a position in Foghorn Therapeutics in Q4 2020 and has held it in 23 quarters since.
  • State Street's Foghorn Therapeutics position peaked at $6.92M in Q4 2021.
  • 103 funds tracked by Wall St. Rank held Foghorn Therapeutics as of Q2 2026.

Based on State Street's 13F filing for Q2 2026, filed 7 Aug 2026.